March 27, 2015 |
Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?
Books espousing behavioural economic theories, such as “Thinking Fast and Slow” authored by Daniel Kahneman, have become essential reading for market researchers looking to improve their understanding of how people think, feel and behave.
This theory can be very useful in consumer research, where we already know the power brands have on influencing purchase decisions. But can behavioural economics theory be applied to the pharmaceutical healthcare industry, where treatment decisions are often made in a highly regulated environment and by educated professionals using sound, rational judgement?
Download and read the complimentary whitepaper at http://bit.ly/1L5YhyM
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.
This content was provided by Inizio
Latest Content from Inizio
All eyes on Spinraza
In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch…
Download our pre-launch checklist
The key to conducting effective rare disease research
Download our third Innovation in #MRX webcast, hosted in partnership with Convosphere, where we discuss how to use social media listening to answer key business questions.Watch here: https://bit.ly/2nM0xvj
Given the colossal amount of personal and professional information that we share online, social media channels such as Facebook and Twitter are fast becoming treasure troves of big data. As…
Our latest infographic outlines the changes to the clinical trial process, accelerated drug approval, fast track of rare disease products and access opportunities in China’s evolving healthcare environment.Find out more here-…
Research Partnership were delighted to exhibit, sponsor and present three papers at the EphMRA conference where Director Richard Head was presented with one of this year’s MR Excellence Awards.Find out…
Research Partnership’s client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks; the main burden of disease is not just…
Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients…
